(Q34468674)

2 August 2017

1 reference

title

Docetaxel: a review of its use in metastatic breast cancer (English)

1 reference

Katherine A Lyseng-Williamson

2 August 2017

metastatic breast cancer

1 reference

1 reference

object named as

Katherine A Lyseng-Williamson

series ordinal

1

0 references

author name string

Caroline Fenton

series ordinal

2

1 reference

2 August 2017

1 January 2005

1 reference

2 August 2017

1 reference

2 August 2017

65

1 reference

2 August 2017

17

1 reference

2 August 2017

2513-2531

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565170-00007

2 August 2017

0 references

cites work

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

12 December 2020

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

12 December 2020

Antitumor activity of docetaxel

1 reference

12 December 2020

Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study

1 reference

12 December 2020

Clinical pharmacokinetics of docetaxel.

1 reference

12 December 2020

Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel

1 reference

12 December 2020

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

1 reference

12 December 2020

Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer.

1 reference

12 December 2020

Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study

1 reference

12 December 2020

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

12 December 2020

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

1 reference

12 December 2020

Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?

1 reference

12 December 2020

Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer

1 reference

12 December 2020

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

12 December 2020

Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.

1 reference

12 December 2020

Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial

1 reference

12 December 2020

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer

1 reference

12 December 2020

Pharmacokinetics of the taxanes

1 reference

12 December 2020

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

1 reference

12 December 2020

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

1 reference

12 December 2020

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

1 reference

12 December 2020

Docetaxel: an update of its use in advanced breast cancer

1 reference

12 December 2020

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer

1 reference

12 December 2020

Taxane containing regimens for metastatic breast cancer

1 reference

12 December 2020

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

1 reference

12 December 2020

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

12 December 2020

Protracted administration of weekly docetaxel in metastatic breast cancer.

1 reference

12 December 2020

The taxoids. Comparative clinical pharmacology and therapeutic potential

1 reference

12 December 2020

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

1 reference

12 December 2020

Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.

1 reference

12 December 2020

Docetaxel as single-agent treatment in elderly patients with advanced breast cancer

1 reference

12 December 2020

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

12 December 2020

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

12 December 2020

Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer

1 reference

12 December 2020

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

12 December 2020

Quality of life in women with advanced breast cancer treated with docetaxel

1 reference

12 December 2020

A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study

1 reference

12 December 2020

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

1 reference

12 December 2020

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

12 December 2020

Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel

1 reference

12 December 2020

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study

1 reference

12 December 2020

Preclinical pharmacology of the taxanes: implications of the differences.

1 reference

12 December 2020

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

1 reference

12 December 2020

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

12 December 2020

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

1 reference

12 December 2020

Recent progress in the clinical development of docetaxel (Taxotere).

1 reference

12 December 2020

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

1 reference

12 December 2020

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

12 December 2020

Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment

1 reference

12 December 2020

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

12 December 2020

Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience

1 reference

12 December 2020

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

1 reference

12 December 2020

Weekly docetaxel (Taxotere) in patients with metastatic breast cancer

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

12 December 2020

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics

1 reference

12 December 2020

Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer

1 reference

12 December 2020

Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial

1 reference

12 December 2020

10.2165/00003495-200565170-00007

Identifiers

DOI

1 reference

PubMed ID

16296875

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

16296875